4D Molecular Therapeutics, Inc. (FDMT)
10.80
-1.05
(-8.86%)
USD |
NASDAQ |
Oct 23, 16:00
10.78
-0.02
(-0.23%)
After-Hours: 20:00
4D Molecular Therapeutics Enterprise Value : 274.20M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 274.20M |
| October 22, 2026 | 332.17M |
| October 21, 2026 | 374.68M |
| October 20, 2026 | 401.19M |
| October 19, 2026 | 356.46M |
| October 16, 2026 | 348.18M |
| October 15, 2026 | 388.49M |
| October 14, 2026 | 351.50M |
| October 13, 2026 | 360.33M |
| October 12, 2026 | 395.67M |
| October 09, 2026 | 413.89M |
| October 08, 2026 | 379.10M |
| October 07, 2026 | 373.03M |
| October 06, 2026 | 371.37M |
| October 05, 2026 | 391.25M |
| October 02, 2026 | 432.66M |
| October 01, 2026 | 442.05M |
| September 30, 2026 | 468.00M |
| September 29, 2026 | 477.94M |
| September 28, 2026 | 481.80M |
| September 25, 2026 | 476.83M |
| September 24, 2026 | 490.08M |
| September 23, 2026 | 506.09M |
| September 22, 2026 | 554.68M |
| September 21, 2026 | 519.35M |
| Date | Value |
|---|---|
| September 18, 2026 | 518.24M |
| September 17, 2026 | 488.43M |
| September 16, 2026 | 437.63M |
| September 15, 2026 | 430.45M |
| September 14, 2026 | 437.63M |
| September 11, 2026 | 405.05M |
| September 10, 2026 | 422.72M |
| September 09, 2026 | 460.82M |
| September 08, 2026 | 485.67M |
| September 04, 2026 | 504.44M |
| September 03, 2026 | 489.53M |
| September 02, 2026 | 502.78M |
| September 01, 2026 | 470.21M |
| August 31, 2026 | 456.95M |
| August 28, 2026 | 487.87M |
| August 27, 2026 | 501.13M |
| August 26, 2026 | 537.01M |
| August 25, 2026 | 545.85M |
| August 24, 2026 | 527.63M |
| August 21, 2026 | 551.92M |
| August 20, 2026 | 566.83M |
| August 19, 2026 | 603.27M |
| August 18, 2026 | 490.63M |
| August 17, 2026 | 480.97M |
| August 14, 2026 | 350.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Imunon, Inc. | 6.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -72.94M |
| Revenue (Quarterly) | 3.781M |
| Total Expenses (Quarterly) | 76.72M |
| EPS Diluted (Quarterly) | -1.038 |
| Gross Profit Margin (Quarterly) | 44.75% |
| Profit Margin (Quarterly) | -1.93K% |
| Earnings Yield | -25.23% |
| Normalized Earnings Yield | -25.23 |